Six-factor-based stratification system for enfortumab vedotin monotherapy in pre-treated patients with metastatic or locally advanced urothelial carcinoma - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

A Six-Factor Stratification Approach for Enfortumab Vedotin Treatment in Previously Treated Patients with Advanced Urothelial Carcinoma

  • By

  • Yuto Matsushita

  • Satoru Taguchi

  • Taku Naiki

  • Gaku Ishikawa

  • Yu Nakamura

  • Jimpei Miyakawa

  • Takashi Nagai

  • Tomoyuki Kaneko

  • Hiroki Kubota

  • Hayato Hoshina

  • Jun Kamei

  • Aya Niimi

  • Yuta Yamada

  • Daisuke Obinata

  • Shigenori Kakutani

  • Masashi Shiozaki

  • Kento Ozawa

  • Michio Noda

  • Daichi Hirata

  • Yuichi Kitagawa

  • Yukihiro Yoshimi

  • Nozomi Sugiyama

  • Nobuhiko Shimizu

  • Yohei Tsubouchi

  • Keigo Sato

  • Kosuke Uchida

  • Shinya Watanabe

  • Jun Takahashi

  • Toshiharu Morikawa

  • Yoichi Mori

  • Takashi Murata

  • Taro Murata

  • Taketo Kawai

  • Takehiro Tanaka

  • Yukari Uemura

  • Tappei Takada

  • Sayuri Takahashi

  • Toshiki Ito

  • Masao Nagata

  • Hideyo Miyazaki

  • Satoshi Kurokawa

  • Yukio Yamada

  • Ryo Sato

  • Atsushi Otsuka

  • Yusuke Sato

  • Hiroaki Nishimatsu

  • Yukihiro Umemoto

  • Hiroshi Furuse

  • Yoshiyuki Akiyama

  • Yutaka Enomoto

  • Satoru Takahashi

  • Tetsuya Fujimura

  • Tohru Nakagawa

  • Hiroshi Fukuhara

  • Takahiro Yasui

  • Haruki Kume

  • Teruo Inamoto

  • September 11, 2026

Share

Original Source(s)

Six-factor-based stratification system for enfortumab vedotin monotherapy in pre-treated patients with metastatic or locally advanced urothelial carcinoma

  • by Yuto Matsushita, Satoru Taguchi, Taku Naiki, Gaku Ishikawa, Yu Nakamura, Jimpei Miyakawa, Takashi Nagai, Tomoyuki Kaneko, Hiroki Kubota, Hayato Hoshina, Jun Kamei, Aya Niimi, Yuta Yamada, Daisuke Obinata, Shigenori Kakutani, Masashi Shiozaki, Kento Ozawa, Michio Noda, Daichi Hirata, Yuichi Kitagawa, Yukihiro Yoshimi, Nozomi Sugiyama, Nobuhiko Shimizu, Yohei Tsubouchi, Keigo Sato, Kosuke Uchida, Shinya Watanabe, Jun Takahashi, Toshiharu Morikawa, Yoichi Mori, Takashi Murata, Taro Murata, Taketo Kawai, Takehiro Tanaka, Yukari Uemura, Tappei Takada, Sayuri Takahashi, Toshiki Ito, Masao Nagata, Hideyo Miyazaki, Satoshi Kurokawa, Yukio Yamada, Ryo Sato, Atsushi Otsuka, Yusuke Sato, Hiroaki Nishimatsu, Yukihiro Umemoto, Hiroshi Furuse, Yoshiyuki Akiyama, Yutaka Enomoto, Satoru Takahashi, Tetsuya Fujimura, Tohru Nakagawa, Hiroshi Fukuhara, Takahiro Yasui, Haruki Kume, Teruo Inamoto

  • September 11, 2026

Related Content

Correction: Case Report: Complete response and prolonged survival to alectinib in a NSCLC patient with metastases harboring a rare WDR43::ALK structural deletion

Cost-Effectiveness of Electronic Patient-Reported Outcome Measure Interventions in Cancer: Systematic Review and Parameter Extraction for Economic Modeling

Retraction Note: TWIST1 activates cancer stem cell marker genes to promote epithelial‑mesenchymal transition and tumorigenesis in esophageal squamous cell carcinoma